Document is current
Any future updates will be listed below
-
Authors
Gunay, Aksu https://orcid.org/0000-0002-2728-1135
Targum, Steven D. https://orcid.org/0000-0003-1054-5197
Leow, Alex D.
Ajilore, Olusola https://orcid.org/0000-0003-0737-0437
Rasenick, Mark M. https://orcid.org/0000-0003-2405-4364
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH120168, R41MH113398, R43 MH097370, R0!MH120168, R01MH120168)
Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs (BX001149, BX004475)
- License Information
-
More Information
Article History
Received: 13 August 2024
Revised: 21 January 2025
Accepted: 20 February 2025
First Online: 4 March 2025
Ethics
: The study was conducted in accordance with the Declaration of Helsinki (1964) and Good Clinical Practices as outlined by the International Conference on Harmonization (1997). This study was approved by the Institutional Review Board of the University of Illinois Chicago (Study #2019-1333). Participants provided written informed consent prior to participating in study procedures and completed an additional electronic consent for the BiAffect app. All participants signed an IRB-approved consent to participate and consent to give blood samples for the UnMASCK study. All participating subjects were compensated for their participation in the study. Methods are used in this study conform to all international, federal, state, local and university guidelines.
: Dr. Targum has received vendor grants and/or consulting fees from Actinogen Medical Ltd., BioXcel Therapeutics, CSA Medical Inc., Deerfield Discovery and Development, LLC, EMA Wellness, ERG Inc., Frequency Therapeutics, Functional Neuromodulation Inc., Karuna Pharmaceuticals, Maplight, Merck Pharmaceuticals, Navitor-Supernus Pharmaceuticals, Neurocrine Bioscience, Pax Neuroscience, and Signant Health during the past 3 years. Dr. Ajilore is a co-founder of KeyWIse AI. He also serves on the advisory boards of Embodied Labs, Sage Therapeutics and Blueprint Health. He is also a consultant for Otsuka. Dr. Leow is an advisor for Buoy health and a consultant for Otsuka USA and ATAI Life Sciences, in addition to being a co-founder of KeyWise AI. Dr. Rasenick is co-founder and chief scientific officer of Pax Neuroscience. In the past three years he has consulted for Otsuka, Inc and has received research support from Lundbeck SA. He is also supported by grants from the Veterans Administration and is a research career scientist of the VA.
